HIV and AIDS Main Section
Hepatitis C Main Section
HIV-HCV Coinfection Main Section
 Google Custom Search
Factors Associated with HCV Viral Load in HIV Positive and Negative Women

By Liz Highleyman

Due to overlapping transmission routes -- in particular injection drug use -- many HIV positive women are coinfected with hepatitis C virus (HCV).

As reported in the April 2008 Journal of Clinical Virology, researchers with the Women's Interagency HIV Study (WIHS) conducted an analysis of the risk factors for and predictors of HCV viremia (detectable viral load) among HIV positive and at-risk women.

The investigators looked at socio-demographic, immunological, and virological factors associated with the presence and level of HCV viremia in 1049 HCV seropositive women, of whom 882 were HIV positive and 167 were HIV negative at entry into the WIHS cohort.

Results

Plasma HCV RNA was detectable in 852 of the 1049 women (81%).

HCV viral loads ranged from 1.2 to 7.8 log10 copies/mL.

Women with detectable HCV viremia were more likely:

to have an HIV RNA level above 100,000 copies/mL (P = 0.0004);

to report smoking (P = 0.01);

to be of black race/ethnicity (P = 0.005).

However, they were less likely to have current or resolved hepatitis B virus (HBV) infection.

HCV RNA levels were higher among women who were older than 35 years or were HIV positive.

Current smoking and a history of drug use (crack/freebase cocaine, marijuana, amphetamines, or heroin) were each associated with both the presence of and a higher level of HCV viremia.


Conclusion

Based on these findings, the study authors recommended, "Substance abuse counseling aimed at eliminating ongoing use of illicit drugs and tobacco may reduce clinical progression, improve response to treatment, and decrease HCV transmission by lowering levels of HCV viremia in women.

4/18/08

Reference
EA Operskalski, WJ Mack, HD Strickler, and others. Factors associated with hepatitis C viremia in a large cohort of HIV-infected and -uninfected women. Journal of Clinical Virology 41(4): 255-263. April 2008.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


FDA-approved Combination Therapies for Chronic HCV Infection

Pegasys + Copegus
PEG-Intron + Rebetol
Intron A + Rebetol
Roferon A + Ribavirin

FDA-approved Therapies
for HIV and AIDS
Protease Inhibitors (PIs)
Note: Most PIs are now used
in combination with low-dose
ritonavir (Norvir)
Agenerase
Agenerase (amprenavir)
Aptivus
Aptivus (tipranavir)
Crixivan
Crixivan (indinavir)
Invirase
Invirase (saquinavir )
Kaletra
Kaletra (lopinavir/ritonavir)
Lexiva
Lexiva (fosamprenavir)
Norvir
Norvir (ritonavir)
Prezista
Prezista (darunavir)
Reyataz
Reyataz (atazanavir)
Viracept
Viracept (nelfinavir)
Nucleoside / Nucleotide
Reverse Transcriptase
Inhibitors (NRTIs)
Combivir
Combivir (zidovudine + lamivudine)
Epivir
Epivir (lamivudine; 3TC)
Emtriva
Emtriva (emtricitabine; FTC)
Epzicom
Epzicom (abacavir + lamivudine)
Retrovir
Retrovir (zidovudine; AZT)
Trizivir
Trizivir (abacavir + zidovudine +lamivudine)
Truvada
Truvada  (tenofovir + emtricitabine)
Videx
Videx (didanosine; ddI)
Viread
Viread (tenofovir)
Zerit
Zerit (stavudine; d4T)
Ziagen
Ziagen (abacavir)
non Nucleoside 
Reverse Transcriptase
 Inhibitors
(nNRTIs)
Rescriptor
Intelence (etravirine)
Rescriptor
Rescriptor (delavirdine)
Sustiva
Sustiva (efavirenz)
Viramune
Viramune (nevirapine)
Entry / Fusion Inhibitors
Fuzeon (enfuvirtide)
Selzentry/Celsentri ( maraviroc)
Fixed-dose Combinations
Atripla
Atripla (efavirenz + emtricitabine + tenofovir)
Combivir
Combivir (zidovudine + lamivudine)
Trizivir
Trizivir (abacavir + zidovudine + lamivudine)
Truvada
Truvada (tenofovir + emtricitabine)
Integrase Inhibitors
Isentress (raltegravir)